IP Library Granted Patent US 10,947,285
Granted Patent B2
US 10,947,285 · App. 15/888,402 · Granted Mar 16, 2021

Compounds, compositions and uses thereof for improvement of bone disorders

Inventors: David Clemmons (Chapel Hill, NC); Gang Xi (Cary, NC); Thomas Delale (Ecully, FR); Michel Julien (Lyons, FR); Thierry Abribat (St-Foy-lès-Lyon, FR)
Assignee: Amolyt Pharma
C07K14/4743A61K38/08A61K38/1754A61P19/08A61P19/10C07K7/06A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,947,285
App. No.
15/888,402
Granted
Mar 16, 2021
Kind
B2
Abstract

The present technology generally relates to peptides of IGFBP-2 that may be used to improve bone disorders. The present technology also generally relates to uses of such peptides in methods for preventing or treating bone disorders and to compositions for such uses.

Claims (7)

1. An isolated peptide consisting of a heparin binding domain (HBD) fragment as set forth in SEQ ID NO: 73.

2. A composition comprising the isolated peptide of claim 1 together with a suitable pharmaceutical excipient.

3. A method for treatment of a bone disorder in a subject in need thereof, the method comprising administering the isolated peptide of claim 1 to the subject in an amount effective to treat the bone disorder in the subject.

4. The method of claim 3 , wherein the bone disorder is selected from: osteoporosis, osteopenia, osteogenesis imperfecta, osteonecrosis, low bone mass, Paget's disease of bone, aseptic prosthetic loosening, metastatic bone disease, rheumatoid arthritis, lupus arthritis, periodontal disease, alveolar bone loss, post-osteotomy, childhood idiopathic bone loss, curvature of the spine, loss of height, and prosthetic surgery.

5. The method of claim 4 , wherein the bone disorder is selected from: a broken bone, a bone defect, a bone transplant, a bone graft, a bone cancer, a joint replacement, a joint repair, a fusion, a facet repair, a bone degeneration, a dental implant, a dental repair, and any combination thereof.

6. The method of claim 3 , wherein the effective amount is from about 1 μg/kg to about 50 mg/kg.

7. The method of claim 3 , wherein said administering is continued for a period of at least about 10 weeks or about 24 weeks.

Assignments (2)
CHANGE OF NAME Recorded Aug 6, 2020
From: ALIZE PHARMA III SAS
To: AMOLYT PHARMA
Reel/Frame 053424/0524 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 23, 2018
From: CLEMMONS, DAVID; XI, GANG; DELALE, THOMAS; JULIEN, MICHEL; ABRIBAT, THIERRY
To: ALIZE PHARMA III SAS
Reel/Frame 047568/0187 →
Continuity (2)
Provisional Application 62455124 · Feb 6, 2017
Related Publication 20180230191A1 · Aug 16, 2018